STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	May 31, 2021	May 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (316,283)	$ (457,970)
Adjustments to reconcile net loss to net cash used in operating activities:
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.	215,926	281,978
Changes in operating assets and liabilities
Prepaids	(521)	10,388
Accounts payable	(2,071)	81,061
Accrued liabilities	18,514	1,063
NET CASH USED IN OPERATING ACTIVITIES	(84,435)	(83,480)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	84,967	83,317
NET CASH PROVIDED BY FINANCING ACTIVITIES	84,967	83,317
NET INCREASE (DECREASE) IN CASH	532	(163)
CASH AT BEGINNING OF PERIOD	62	163
CASH AT END OF PERIOD	$ 594	$ 0